In ₹ Crore except Per Share Latest Annual	JLHL FY26	APOLLOHOSP FY26	MAXHEALTH FY26	KIMS FY26	Peer Average
Valuation — at last close
P/E	◆ 8.79×	60.72×	57.39×	116.50×	78.21× -89%
P/B	◆ 1.10×	12.44×	7.71×	12.50×	10.88× -90%
EV/EBITDA	◆ 4.87×	32.35×	38.17×	39.36×	36.63× -87%
Market Cap	₹1,705 Cr	₹1.18L Cr	₹82,828 Cr	₹28,100 Cr	₹76,281 Cr -98%
Growth
Revenue CAGR 3Y	18.89%	14.94%	◆ 22.43%	21.12%	19.50% -3%
Revenue CAGR 5Y	—	19.03%	◆ 27.30%	24.04%	23.46%
Net Income CAGR 3Y	◆ 39.77%	33.35%	9.34%	-12.87%	9.94% +300%
Revenue YoY (latest Q)	15.97%	20.56%	20.31%	◆ 35.33%	25.40% -37%
Net Income YoY (latest Q)	-1.95%	◆ 38.41%	-15.64%	-56.00%	-11.08% +82%
Profitability
EBITDA Margin	22.89%	14.94%	◆ 26.79%	20.54%	20.76% +10%
Net Income Margin	13.27%	7.94%	◆ 17.23%	6.20%	10.46% +27%
Return on Common Equity	13.41%	◆ 21.95%	14.33%	11.01%	15.76% -15%
Return on Capital Employed	13.08%	◆ 18.20%	12.63%	9.09%	13.31% -2%
Return on Assets	9.29%	◆ 9.35%	8.89%	3.59%	7.28% +28%
Credit & Quality
Total Debt/Equity	0.33×	0.57×	◆ 0.32×	1.27×	0.72× -54%
Interest Coverage	◆ 7.83×	6.44×	7.64×	2.56×	5.55× +41%
Scale — latest FY
Revenue / Total Income	₹1,500 Cr	₹25,229 Cr	₹8,373 Cr	₹3,905 Cr	₹12,502 Cr -88%
Net Income	₹199 Cr	₹2,003 Cr	₹1,442 Cr	₹242 Cr	₹1,229 Cr -84%
Total Assets	₹2,383 Cr	₹22,197 Cr	₹17,231 Cr	₹7,759 Cr	₹15,729 Cr -85%
EPS	₹29.59	₹135.04	₹14.83	₹6.03	₹51.97 -43%
Book Value per Share	₹235.5	₹659.26	₹110.43	₹56.19	₹275.29 -14%

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.